Înscrieri al 32-lea CONGRES SRROM ”Terapii inovatoare în oncologia de precizie” – 

Click aici

Volum 21 Numarul 1, 2015

5 Dear RSRMO members

Ovidiu Coza

12 Epidemiological Study of Cervix Cancer in Bihor County between 2003 – 2012

Elisabeta Patca1, Dana Rahota2, Daniela Berdea2, Adela Patcas3

1) Clinical Hospital ,,Gavril Curteanu,, Radiotherapy Department Oradea; 2) University of Oradea, Faculty of Medicine and Pharmacy; 3) University of Medicine and Pharmacy ,,Iuliu Hafieganu ,, Cluj Napoca

Purpose : A retrospective study to evaluate the epidemiology of cervix cancer in our county. Material and Methods: This study is based on data collected from the Territorial Cancer Registry between 2003 to 2012. The statistic analysis was performed with the EPIINFO version 6.0. application of the CDC/ Center of Disease and Control Prevention. For the survival ratio we used the Kaplan- Maier method. Results: Cervix cancer is the second cancer type in Bihor after breast cancer : 20. 5 % vs 30.5 %. In 2003 cervix cancer represented 26% of cases against 16.4 % in 2012 of all women carcinoma. The study by ages of cervix cancer reveals that 60% of patients were in the group 40-49 years. According to the stages we observed that stage 0 was: 31% , stage I : 22.7% , stage II:20% , stage 3:15.6% , stage IV:10.6%. The death index , DC(%) decreased from 17.3% in 2003to 5.4 % in 2010. The mortality of cervix cancer in this period was 17.44 %000 while in 2003 it peaked at 25.63%000 and in 2010 decreased at: 7.07 %000. Conclusions: Cervix cancer in our county remains the second neoplasm after breast cancer, but the incidence and mortality has decreased in time. We also observed that the number of early stages increased due to screening programs initiated in our county.

Key words: cervix cancer, epidemiology

Download pdf-paper

15 Extrahepatic Metastases of Hepatocellular Carcinoma: a Case Report

Andrea Craciunescu1, Tudor-Eliade Ciuleanu1,2, Dana Iancu1, Cristina Mocan1

1) Ion Chiricufa Cancer Institute, Cluj-Napoca; 2) Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca,


Hepatocellular carcinoma (HCC) is a vascular tumor with poor prognosis and a median survival less than one year, if left untreated. The treatment of HCC depends entirely on the tumor stage. Potentially curative partial hepatic resection should be reserved for patients with a stage I or II tumor. Patients with an advanced tumor stage or with poor hepatocel-lular reserves are not candidates for these curative surgical treatments and are left with systemic therapy only. We report the case of a 70- year old male who presented with chest wall and pulmonary metastases of an undifferentiated carci-noma, that proved to be extrahepatic metastases of HCC.

Key words: Hepatocellular carcinoma, metastasis, treatment

Download pdf-paper

18 Cervical Adenocarcinoma. Past, Present and Future

Irina Todor1, Viorica Nagy1,2

1) luliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2) Prof. Dr. Ion Chiricuta Institute of

Oncology, Cluj-Napoca


Due to preventive measures taken in the Western world, cancer of the cervix is placed in the category of rare cancers. Cervix adenocarcinoma represents 15% to 20% from cervical cancers, so it is more a rare cancer. Staging and current treatments of cervical cancer are not differentiated according to the histology of adenocarcinoma. However the risk of metastasis and death is higher for adenocarcinoma although the response is similar to patients with squamous cell cancer. The CA125 marker has proven to be an important predictor factor and HER2 / new when present is associated with an aggressive biological behavior. AJCC staging manual suggests the following 5-year survival rates: 80-93% for early stages-0, IA, IB, 58-63% for IIA, IIB, 32-35% for stages IIIA, IIIB, and low survival rates for stage IV, only 15%.

Key words: cervical cancer, adenocarcinoma (ADC), rare cancer.

Download pdf-paper

27 Foreword

Viorica Nagy

29 Progress in the multidisciplinarycancer treatment

31 Progress in the multidisciplinarycancer treatment


Highlights in Oncology

43 Young Romanian Radiotherapists and Oncologists Group (YRROG) Forum 1st edition 20th of March 2015 – a real success

Claudiu Hopirtean, Radu Vidra, Andrea Craciunescu

45 Guidance for Authors